Avedro

# Avedro: High-Level Overview

Avedro is an ophthalmic medical technology company specializing in corneal cross-linking treatments and refractive correction technologies.[1][5] The company develops and commercializes devices and pharmaceutical products designed to treat corneal ectatic disorders—conditions where the cornea weakens and thins—while also enhancing vision correction outcomes.[5] Avedro serves ophthalmologists and patients seeking alternatives to eyeglasses and contact lenses, addressing a critical gap in corneal disease management where few effective treatment options existed.[5]

The company's primary product portfolio centers on the KXL® System, a corneal cross-linking device that stabilizes weakened corneas through a combination of riboflavin formulations and ultraviolet light exposure.[7] This technology treats keratoconus (a progressive corneal disease) and is used in conjunction with LASIK procedures (marketed as LASIK Xtra®).[1][7] Beyond cross-linking, Avedro has expanded into broader ophthalmic therapies, including drug delivery platforms and glaucoma management solutions.[2]

# Origin Story

Avedro was founded in 2002 and is based in Waltham, Massachusetts.[2][6] The company emerged during a period when corneal cross-linking technology was gaining recognition in Europe but remained largely unavailable in the United States.[1] This geographic gap created the foundational opportunity: Avedro positioned itself to bridge the transatlantic divide by developing FDA-approved versions of cross-linking treatments for the American market.

The company achieved significant early traction through regulatory approvals. In April 2016, Avedro received FDA approval for its Photrexa® formulations and KXL® System—a landmark moment that validated the technology's safety and efficacy for U.S. patients.[5] Prior to this, the company had secured CE Mark approval in Europe (2010) and Chinese regulatory approval (2015), demonstrating its ability to navigate multiple regulatory environments.[5] This international expansion strategy positioned Avedro as a global player in a niche but growing market.

The company went public in February 2019 on the NASDAQ under the ticker AVDR, raising approximately $70 million at an IPO price of $14 per share.[6] However, this public status proved temporary: in November 2019—less than a year after its IPO—Avedro was acquired by Glaukos, a larger ophthalmic medical device company.[2] This acquisition reflected the consolidation dynamics in specialized medical device markets, where larger players acquire innovative technologies to expand their portfolios.

# Core Differentiators

• Proprietary cross-linking technology: The KXL® System combines hardware (a mobile, touchscreen-equipped device with wireless controls) and pharmaceutical components (riboflavin formulations) in an integrated treatment protocol.[7] This bundled approach creates switching costs and positions Avedro as a complete solution provider rather than a component supplier.

• Multiple treatment protocols: The KXL® System offers four preset protocols plus user-programmable options, enabling clinicians to customize treatments for epithelium-off, accelerated, pulsed, or continuous procedures.[7] This flexibility differentiates it from single-protocol competitors.

• Regulatory breadth: Avedro achieved approvals across three major markets (U.S., Europe, China) before acquisition, demonstrating the robustness of its regulatory strategy and the universal applicability of its technology.[5]

• Expanded therapeutic scope: Beyond corneal cross-linking, Avedro developed capabilities in drug delivery platforms and glaucoma management, positioning it as a multi-indication ophthalmic company rather than a single-disease specialist.[2]

# Role in the Broader Tech Landscape

Avedro rode the wave of precision medicine and device-drug combination therapies—a trend that gained momentum in the 2010s as regulators and payers increasingly valued integrated solutions over standalone devices or drugs. The company's emergence also reflected growing recognition of corneal diseases as a significant unmet medical need, particularly as refractive surgery (LASIK) became more common and created new patient populations at risk for ectasia.

The timing was critical: as LASIK adoption accelerated globally, the incidence of post-LASIK ectasia increased, creating demand for stabilization treatments. Avedro positioned itself at this intersection, offering a preventive solution (LASIK Xtra®) that could be bundled with refractive surgery, thereby embedding itself into the standard surgical workflow.

Within the broader ophthalmic device ecosystem, Avedro represented a shift toward minimally invasive, office-based procedures that could be performed by practicing ophthalmologists rather than requiring specialized surgical centers. This democratization of treatment access expanded the addressable market and accelerated adoption.

# Quick Take & Future Outlook

Avedro's acquisition by Glaukos in 2019 marked a transition from independent innovator to integrated portfolio asset. Under Glaukos ownership, the KXL® System benefits from expanded distribution networks and cross-selling opportunities within Glaukos's broader glaucoma and corneal care franchises.[7] The company's future trajectory will likely be shaped by:

• Market penetration in underserved regions: While Avedro achieved regulatory approvals in major markets, adoption in emerging economies remains limited. Glaukos's global infrastructure may accelerate this expansion.

• Indication expansion: The underlying cross-linking technology has potential applications beyond keratoconus and post-LASIK ectasia, including other corneal dystrophies and potentially retinal conditions.

• Competitive pressure: As the cross-linking market matures, competing technologies and lower-cost alternatives may emerge, requiring continued innovation in device design and treatment protocols.

Avedro's story illustrates how specialized medical device companies can achieve outsized impact by identifying regulatory gaps, developing integrated solutions, and executing disciplined international expansion—ultimately becoming attractive acquisition targets for larger players seeking to strengthen their therapeutic portfolios.